Pharma · Public company · Boston, MA, US
Vertex Pharmaceuticals Inc
Ticker VRTX · SEC CIK 0000875320
Track this companyFree. Adds Vertex Pharmaceuticals Inc to your Dealase workspace and tells you when its record changes.
Clinical trials2525 recruiting or active
Pipeline programs24From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline24
- CTX001Phase 3 · Beta-ThalassemiaClinicalTrials.gov · fetched Nov 12, 2026
- CTX001Phase 3 · Sickle Cell DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- PovetaciceptPhase 3 · Immunoglobulin A NephropathyClinicalTrials.gov · fetched Nov 12, 2026
- PovetaciceptPhase 3 · Primary Membranous NephropathyClinicalTrials.gov · fetched Nov 12, 2026
- PregabalinPhase 3 · Diabetic Peripheral Neuropathic PainClinicalTrials.gov · fetched Nov 12, 2026
- SuzetriginePhase 3 · Diabetic Peripheral Neuropathic PainClinicalTrials.gov · fetched Nov 12, 2026
- TacrolimusPhase 3 · Primary Membranous NephropathyClinicalTrials.gov · fetched Nov 12, 2026
- VX-017Phase 3 · Diabetes Mellitus, Type 1ClinicalTrials.gov · fetched Nov 12, 2026
- VX-121/TEZ/D-IVAPhase 3 · Cystic FibrosisClinicalTrials.gov · fetched Nov 12, 2026
- VX-147Phase 3 · Proteinuric Kidney DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- VX-880Phase 3 · Diabetes Mellitus, Type 1ClinicalTrials.gov · fetched Nov 12, 2026
- PovetaciceptPhase 2 · Myasthenia Gravis, GeneralizedClinicalTrials.gov · fetched Nov 12, 2026
- VX-264Phase 2 · Type 1 DiabetesClinicalTrials.gov · fetched Nov 12, 2026
- VX-407Phase 2 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)ClinicalTrials.gov · fetched Nov 12, 2026
- VX-670Phase 2 · Myotonic Dystrophy Type 1 (DM1)ClinicalTrials.gov · fetched Nov 12, 2026
- 14C-VX-407Phase 1 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)ClinicalTrials.gov · fetched Nov 12, 2026
- D-IVAPhase 1 · Cystic FibrosisClinicalTrials.gov · fetched Nov 12, 2026
- DeutivacaftorPhase 1 · Cystic FibrosisClinicalTrials.gov · fetched Nov 12, 2026
- ELX/TEZ/IVAPhase 1 · Cystic FibrosisClinicalTrials.gov · fetched Nov 12, 2026
- TEZPhase 1 · Cystic FibrosisClinicalTrials.gov · fetched Nov 12, 2026
- TezacaftorPhase 1 · Cystic FibrosisClinicalTrials.gov · fetched Nov 12, 2026
- VX-272Phase 1 · Cystic FibrosisClinicalTrials.gov · fetched Nov 12, 2026
- VX-581Phase 1 · Cystic FibrosisClinicalTrials.gov · fetched Nov 12, 2026
- SuzetriginePainClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- Suzetrigine (Journavx) as Multimodal Therapy for Pain Management in Adults Undergoing Surgery for Hip FracturePHASE4 · NOT_YET_RECRUITING · started Jan 5, 2027ClinicalTrials.gov NCT07905404 · fetched Nov 12, 2026
- Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral DosePHASE1 · RECRUITING · started Oct 16, 2026ClinicalTrials.gov NCT07868926 · fetched Nov 12, 2026
- Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) ExtensionRECRUITING · started Oct 15, 2026ClinicalTrials.gov NCT07700225 · fetched Nov 12, 2026
- Assessing Suzetrigine for Pain Reduction Following Ureteroscopic SurgeryPHASE3 · NOT_YET_RECRUITING · started Oct 1, 2026ClinicalTrials.gov NCT07654296 · fetched Nov 12, 2026
- A Phase 1 Relative Bioavailability Study of a VX-581 Tablet FormulationPHASE1 · ACTIVE_NOT_RECRUITING · started Sep 23, 2026ClinicalTrials.gov NCT07813039 · fetched Nov 12, 2026
- A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A NephropathyPHASE3 · ENROLLING_BY_INVITATION · started Sep 17, 2026ClinicalTrials.gov NCT07807995 · fetched Nov 12, 2026
- A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia GravisPHASE2 · ACTIVE_NOT_RECRUITING · started May 13, 2026ClinicalTrials.gov NCT07501702 · fetched Nov 12, 2026
- Evaluation of Pain Treatment After Total Knee ArthroplastyPHASE4 · ACTIVE_NOT_RECRUITING · started Apr 24, 2026ClinicalTrials.gov NCT07538570 · fetched Nov 12, 2026
- Suzetrigine for Non-Mastectomy Breast SurgeryPHASE4 · ENROLLING_BY_INVITATION · started Apr 14, 2026ClinicalTrials.gov NCT07463430 · fetched Nov 12, 2026
- Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsPHASE1 · RECRUITING · started Feb 25, 2026ClinicalTrials.gov NCT07437105 · fetched Nov 12, 2026
- Evaluation of VX-581 in Healthy Participants and in Participants With Cystic FibrosisPHASE1 · RECRUITING · started Dec 9, 2025ClinicalTrials.gov NCT07283770 · fetched Nov 12, 2026
- Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral NeuropathyPHASE3 · RECRUITING · started Nov 21, 2025ClinicalTrials.gov NCT07231419 · fetched Nov 12, 2026
- Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)PHASE2 · ACTIVE_NOT_RECRUITING · started Nov 19, 2025ClinicalTrials.gov NCT07161037 · fetched Nov 12, 2026
- Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)PHASE2_PHASE3 · RECRUITING · started Sep 30, 2025ClinicalTrials.gov NCT07204275 · fetched Nov 12, 2026
- A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type IPHASE2 · ENROLLING_BY_INVITATION · started Apr 28, 2025ClinicalTrials.gov NCT06926621 · fetched Nov 12, 2026
- Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney DiseaseACTIVE_NOT_RECRUITING · started Dec 19, 2024ClinicalTrials.gov NCT06747572 · fetched Nov 12, 2026
- Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)PHASE3 · ACTIVE_NOT_RECRUITING · started Dec 18, 2024ClinicalTrials.gov NCT06696443 · fetched Nov 12, 2026
- Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral NeuropathyPHASE3 · RECRUITING · started Oct 1, 2024ClinicalTrials.gov NCT06628908 · fetched Nov 12, 2026
- A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Feb 20, 2024ClinicalTrials.gov NCT06185764 · fetched Nov 12, 2026
- A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 DiabetesPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started May 16, 2023ClinicalTrials.gov NCT05791201 · fetched Nov 12, 2026
- A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination TherapyPHASE3 · ACTIVE_NOT_RECRUITING · started Nov 8, 2022ClinicalTrials.gov NCT05444257 · fetched Nov 12, 2026
- Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)PHASE3 · ACTIVE_NOT_RECRUITING · started May 2, 2022ClinicalTrials.gov NCT05329649 · fetched Nov 12, 2026
- Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney DiseasePHASE2_PHASE3 · ACTIVE_NOT_RECRUITING · started Mar 30, 2022ClinicalTrials.gov NCT05312879 · fetched Nov 12, 2026
- A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 DiabetesPHASE3 · RECRUITING · started Mar 29, 2021ClinicalTrials.gov NCT04786262 · fetched Nov 12, 2026
- A Long-term Follow-up Study in Participants Who Received CTX001PHASE3 · ENROLLING_BY_INVITATION · started Jan 20, 2021ClinicalTrials.gov NCT04208529 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 2, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 20, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 1, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 7, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 31, 2026 · fetched Nov 12, 2026